Introduction
The European Cancer Anaemia Survey study involving 24 countries reported that 83% of cancer patients receiving chemotherapy develop anemia during their course of illness. [1, 2] Such patients with anemia also have fatigue, weakness, breathlessness, poor performance status, and worse quality of life (QoL). [3, 4] Anemia in cancer patients has also been associated with higher mortality and poorer prognosis. [5] One important factor is due to underreporting of chemotherapy-induced anemia (CIA) -with more than half of them not receiving anemia directed therapy during treatment of their cancer.
Alkylating agents and platinum-based chemotherapy have double the risk of anemia. [1, 6] Low baseline hemoglobin (Hb) (≤12.9 g/dL in females and ≤13.4 dL in males) and concurrent treatment with chemotherapy/radiation therapy are also risk factors of CIA. [1] Patients with lung cancer or gynecologic cancer also have higher risk for anemia, being 39% for single-modality treatment (either chemotherapy or radiation therapy) and 50% for concomitant chemoradiotherapy (50%). [3] Among cancer patients receiving chemotherapy and developing anemia (Hb ≤11 g/dL), 63% are shown to document moderate-to-severe fatigue. [7] Other features commonly seen in CIA, such as insomnia, anorexia, This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
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Supportive Care and Others ORIGINAL ARTICLE platinum-based combination chemotherapy. Drugs used included gemcitabine, pemetrexed, 5-fluorouracil, docetaxel, paclitaxel, oxaliplatin, capecitabine, adriamycin, carboplatin, cisplatin, And darbepoetin (Cresp, Dr. Reddy's Laboratories, Hyderabad, Telengana, India) which were administered 500 µg subcutaneously for every three weeks.
Of the 274 patients who commenced therapy (CT), 233 were able to complete the intended CT (29 had Progressive Disease (PD), 5 due to toxicity, and 7 either died or were lost to FU). Of the 233 patients who were evaluated at the end of CT, 61 (26.18%) achieved complete response, 107 (45.92%) partial response, and 65 (27.90%) stable disease.
Three-weekly Cresp doses were given for a median of four times (range: 1-8 times). The major reason for missing or discontinuing Cresp was due to patient's wish (financial reasons). Cresp was discontinued due to toxicity only in two cases. The median baseline Hb was 8.9 g/dl (range: 6-10 g/dl). The last documented Hb was a median of 11.2 g/dl (range: 9.41-14.6 g/dl). Eight patients required RBC transfusion and were considered as failure of Cresp.
Discussion
Erythropoietin (EPO) is produced endogenously in humans and is responsible for regulating maturation, proliferation, and differentiation of RBCs. [17] Chemotherapy myelosuppression reduces the endogenous production of EPO, leading to anemia. Thus, the use of pharmacological doses of ESA treatments is aimed at overcoming the effect of chemotherapy-induced myelosuppression in the EPO-deficient setting.
Cancer patients on chemotherapy need support when their Hb concentration falls below 10 g/dL. [18] Darbepoetin alfa (as compared to conventional EPO) needs to be administered less frequently -having a longer half-life with improved biologic activity. [12, 15] Close monitoring of patients receiving darbepoetin is mandatory for efficacy, toxicity, and dose modification as per guidelines, and the US Food and Drug Administration even issued a black box warning. [19] However, the experience on either side of the Atlantic ocean has been a lesson in contrast. While the USA floundered and faced significant toxicity, Europe was able to continue using EPO without safety issues. The fundamental difference was in the adherence to the guidelines in Europe -with careful attention to all recommendations -in which patients should consider EPO, Hb level at which to start EPO, dose of EPO to be given, frequency of monitoring, criteria for dose adjustments, as well as level of Hb at which to discontinue further EPO.
These are the largest data on the use of Cresp (darbepoetin biosimilar) in cancer patients. They reflect its use in a multitude of common solid tumors including head-and-neck, lung, and breast cancers. Administration of long-acting Cresp allowed seamless integration into the patients' chemotherapy schedule, without increasing the need to visit health-care professionals/hospitals. The median increase in the Hb level from baseline was 2.3 g/ dl, indicating a very good response. Eight patients required RBC transfusions and two other patients required discontinuation of Cresp due to toxicity. This gives an overall failure rate of only 4.29% (10/233). [20] [21] [22] Anemia-related symptoms also showed improvement in the majority of patients. Toxicity was in line with published literature, and there were no unexpected or new safety concerns.
Initial fear that darbepoetin is associated with higher (22%) cardiovascular and/or thromboembolic adverse events as compared to placebo (15%) has not been proven to be appropriate in subsequent randomized controlled trials. [23] Hence, the fear of adverse impact on overall survival has also been shown to be incorrect by several recent publications. [24] [25] [26] [27] [28] Thus, the correct use of ESAs to treat anemia in cancer patients receiving myelosuppressive chemotherapy is appropriate, safe, and beneficial. [29] In order to maximize the benefit for patients, it is recommended to follow published guidelines in general. [30, 31] For individual patients, management may also be necessary to personalize information on energy conservation methods, diet modification, and graded exercise scheduling -aspects entirely under the control of the patient/ family, and following related doctors instructions are vital to optimise treatment benefit. Doing so has also been shown to provide cost-effective management of patients. [32] In summary, the take-home messages are shown in Table 4 . 
Conclusion
Darbepoietin is safe and effective in the prevention and management of anemia among patients receiveing myselosuppressive chemotherapy. Cresp should be considered in all solid tumor patients with high risk of chemotherapy induced anemia as well as those who develop the anemia while on chemotherapy.
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